• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hess John B bought $1,997,584 worth of shares (3,904 units at $511.68) (SEC Form 4)

    4/17/25 4:06:04 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance
    Get the next $GS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HESS JOHN B

    (Last) (First) (Middle)
    C/O GOLDMAN SACHS & CO. LLC
    200 WEST STREET

    (Street)
    NEW YORK NY 10282

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GOLDMAN SACHS GROUP INC [ GS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.01 per share 04/15/2025 P 836 A $507.96(1) 836 D
    Common Stock, par value $0.01 per share 04/15/2025 P 344 A $509.08(2) 1,180 D
    Common Stock, par value $0.01 per share 04/15/2025 P 353 A $510.23(3) 1,533 D
    Common Stock, par value $0.01 per share 04/15/2025 P 444 A $511.34(4) 1,977 D
    Common Stock, par value $0.01 per share 04/15/2025 P 384 A $512.24(5) 2,361 D
    Common Stock, par value $0.01 per share 04/15/2025 P 393 A $513.22(6) 2,754 D
    Common Stock, par value $0.01 per share 04/15/2025 P 801 A $514.42(7) 3,555 D
    Common Stock, par value $0.01 per share 04/15/2025 P 176 A $515.31(8) 3,731 D
    Common Stock, par value $0.01 per share 04/15/2025 P 173 A $517.45(9) 3,904 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (10) 04/15/2025 A 50 (10) (10) Common Stock, par value $0.01 per share 50 $0 383 D
    Explanation of Responses:
    1. Reflects a weighted average sale price of $507.96 per share, at prices ranging from $507.58 to $508.56 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    2. Reflects a weighted average sale price of $509.08 per share, at prices ranging from $508.64 to $509.41 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    3. Reflects a weighted average sale price of $510.23 per share, at prices ranging from $509.75 to $510.71 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    4. Reflects a weighted average sale price of $511.34 per share, at prices ranging from $510.79 to $511.70 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    5. Reflects a weighted average sale price of $512.24 per share, at prices ranging from $511.89 to $512.79 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    6. Reflects a weighted average sale price of $513.22 per share, at prices ranging from $512.96 to $513.95 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    7. Reflects a weighted average sale price of $514.42 per share, at prices ranging from $513.96 to $514.95 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    8. Reflects a weighted average sale price of $515.31 per share, at prices ranging from $515.00 to $515.74 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    9. Reflects a weighted average sale price of $517.45 per share, at prices ranging from $517.19 to $517.75 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    10. Represents Restricted Stock Units ("RSUs") granted for the Reporting Person's first quarter 2025 Annual Retainer. Shares of the Issuer's common stock underlying these RSUs will be delivered approximately 90 days after the retirement of the Reporting Person from the Issuer's Board of Directors.
    Remarks:
    /s/ Jamie A. Greenberg, Attorney-in-fact 04/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GS

    DatePrice TargetRatingAnalyst
    4/7/2025$558.00Overweight → Equal-Weight
    Morgan Stanley
    4/4/2025$560.00Outperform → Neutral
    Daiwa Securities
    3/19/2025Outperform → Perform
    Oppenheimer
    2/27/2025$690.00 → $660.00Outperform → Mkt Perform
    Keefe Bruyette
    1/6/2025$610.00Buy → Neutral
    UBS
    11/26/2024$569.00 → $608.00Buy → Hold
    HSBC Securities
    7/2/2024Buy → Neutral
    Seaport Research Partners
    4/16/2024$465.00Hold → Buy
    Argus
    More analyst ratings

    $GS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVISTA HEALTHCARE PARTNERS CLOSES CONTINUATION FUND FOR GCM

      Goldman Sachs Alternatives served as lead investor; additional investments from BlackRock Secondaries & Liquidity Solutions NEW YORK, June 24, 2025 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced the successful close of Avista Healthcare Partners CV II, L.P., a single-asset continuation fund for GCM, a leading outsourced manufacturer of complex precision components for high-growth medical technology end markets. The continuation fund, managed by Avista, is anchored by commitments from funds managed by Secondaries at Goldman Sachs Alternatives, with additional investments from funds managed by BlackRock Se

      6/24/25 4:30:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs Asset Management Announces Liquidation of Two Exchange-Traded Funds

      Goldman Sachs Asset Management ("GSAM"), the investment adviser for the Goldman Sachs Future Consumer Equity ETF and Goldman Sachs Future Planet Equity ETF (each, a "Fund" and collectively, the "Funds"), announced today that the Funds' Board of Trustees, at the recommendation of GSAM, has approved a plan of liquidation for each Fund (collectively, the "Plans"). Under the Plans, which are effective today, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval. Shareholders of the Funds may sell their shares on the Funds' listing exchange, NYSE Arca, Inc. ("NYSE Arca"), u

      6/18/25 4:30:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • BMO Launches Alpha Managers Hedge Fund, in Collaboration with Goldman Sachs Asset Management

      /NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OR TO U.S. PERSONS/ TORONTO, June 10, 2025 /CNW/ - BMO Global Asset Management ('BMO GAM') today announced the launch of its new Alpha Managers Hedge Fund ('Fund'), complementing BMO GAM's innovative suite of alternative investment strategies for accredited investors. The new fund combines high-conviction strategies from global hedge fund managers and aims to deliver alpha, low volatility and less correlated returns to traditional asset classes. BMO GAM's Alpha Managers Hedge Fund portfolio was designed in collaboration with Goldman Sachs Asset Management ('GSAM') and draws upon the combined expertise of

      6/10/25 6:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Goldman Sachs from Overweight to Equal-Weight and set a new price target of $558.00

      4/7/25 11:55:54 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded Goldman Sachs from Outperform to Neutral and set a new price target of $560.00

      4/4/25 8:36:56 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs downgraded by Oppenheimer

      Oppenheimer downgraded Goldman Sachs from Outperform to Perform

      3/19/25 8:14:15 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    SEC Filings

    See more
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      6/27/25 4:50:55 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      6/27/25 4:42:40 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      6/27/25 4:26:15 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance